A clinical study comparing polymer and gold fiducials for prostate cancer radiotherapy.

image guided radiotherapy polymer fiducials prostate cancer radiotherapy verification

Journal

Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867

Informations de publication

Date de publication:
2022
Historique:
received: 19 08 2022
accepted: 30 12 2022
entrez: 23 2 2023
pubmed: 24 2 2023
medline: 24 2 2023
Statut: epublish

Résumé

Image guidance with gold fiducials improves outcomes of prostate radiotherapy. However, gold produces artefact on CT imaging, interfering with contouring and verification. The purpose of this study was to compare polymer to standard gold fiducials using radiotherapy imaging modalities to assess the visibility and artefact. Twenty eight patients with locally advanced prostate cancer were enrolled, half had three polymer fiducials implanted into the prostate and half underwent insertion of gold fiducials. Patients were imaged with CT, T2 weighted MRI, cone-beam CT (CBCT) and planar KV images. Fiducials were scored for visibility and assessed for CT artefact in surrounding prostate tissue. The artefact was quantified from Hounsfield number histograms and separated into percentile ranges and proportion of voxels in HU normal tissue range of a 2cm sphere surrounding the fiducial. Gold and polymer fiducials were sufficiently visible for CT and CBCT verification. The gold fiducials could be visualized well on KV planar imaging; however, the polymer markers were obscured by pelvic bones. Neither polymer nor gold fiducials could be visualized on MRI. The polymer fiducial produced less artefact than gold on CT, having less voxel spread for the HU percentile ranges and a greater proportion of voxels in the normal tissue range. Polymer fiducials are a more suitable fiducial than gold for CT/CBCT in prostate cancer radiotherapy, demonstrating minimal artefact and good visibility on CT. However, they were not well seen on MRI or KV imaging and thus not suitable for co-registration or planar KV verification.

Identifiants

pubmed: 36818674
doi: 10.3389/fonc.2022.1023288
pmc: PMC9930895
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1023288

Informations de copyright

Copyright © 2023 Lim Joon, Berry, Harris, Tacey, Smith, Lawrentschuk, Schneider, Fraser, Hall, Chao, Foroudi, Jenkins, Angus, Wada, Sengupta and Khoo.

Déclaration de conflit d'intérêts

The polymer fiducials (14 sets of 3) were supplied by the company alphaXRT Pty Ltd for the study. The authors have no other conflicts of interest to declare.

Références

Int J Radiat Oncol Biol Phys. 2011 Jul 15;80(4):1056-63
pubmed: 21147514
Radiother Oncol. 2013 May;107(2):140-6
pubmed: 23684585
Int J Radiat Oncol Biol Phys. 2007 Jul 1;68(3):912-9
pubmed: 17459605
Cancer Treat Rev. 2009 Nov;35(7):540-6
pubmed: 19493624
Int J Radiat Oncol Biol Phys. 2002 Aug 1;53(5):1097-105
pubmed: 12128107
Cancer. 2009 Aug 1;115(15):3446-56
pubmed: 19484790
Lancet Oncol. 2010 Nov;11(11):1066-73
pubmed: 20933466
Technol Cancer Res Treat. 2015 Jun;14(3):298-304
pubmed: 25230715
J Clin Oncol. 2006 May 1;24(13):1990-6
pubmed: 16648499
Int J Radiat Oncol Biol Phys. 2007 Mar 1;67(3):942-53
pubmed: 17293243
Cancer Treat Rev. 2009 Feb;35(1):9-17
pubmed: 18926640
J Appl Clin Med Phys. 2012 Sep 06;13(5):3976
pubmed: 22955665
Int J Radiat Oncol Biol Phys. 2005 Aug 1;62(5):1291-6
pubmed: 16029784
Rep Pract Oncol Radiother. 2017 Nov-Dec;22(6):502-506
pubmed: 29123458
Phys Med Biol. 2006 Oct 21;51(20):5183-97
pubmed: 17019032
Lancet Oncol. 2007 Jun;8(6):475-87
pubmed: 17482880
Phys Med Biol. 2012 Jan 7;57(1):155-72
pubmed: 22127351
Clin Oncol (R Coll Radiol). 2012 Sep;24(7):461-73
pubmed: 22673744
Int J Radiat Oncol Biol Phys. 2009 Jul 15;74(4):1283-9
pubmed: 19427750
Int J Radiat Oncol Biol Phys. 2008 Mar 15;70(4):1151-7
pubmed: 17892920
Int J Radiat Oncol Biol Phys. 2009 Aug 1;74(5):1405-18
pubmed: 19616743
Acta Oncol. 2019 Oct;58(10):1352-1357
pubmed: 31241387
Phys Med Biol. 2007 Jun 7;52(11):2937-52
pubmed: 17505081
Int J Radiat Oncol Biol Phys. 2012 Sep 1;84(1):125-9
pubmed: 22330997
Radiat Oncol. 2014 Feb 04;9:44
pubmed: 24495815
Int J Radiat Oncol Biol Phys. 2009 Aug 1;74(5):1609-16
pubmed: 19616746
Int J Radiat Oncol Biol Phys. 2009 Jan 1;73(1):53-60
pubmed: 18501530
Int J Radiat Oncol Biol Phys. 2004 Sep 1;60(1):329-34
pubmed: 15337572
J Appl Clin Med Phys. 2011 Apr 18;12(3):3453
pubmed: 21844856
Sci Rep. 2021 Apr 26;11(1):8931
pubmed: 33903651

Auteurs

Daryl Lim Joon (D)

Radiation Oncology Department, Olivia Newton-John Cancer Centre, Heidelberg, VIC, Australia.

Colleen Berry (C)

Radiation Oncology Department, Olivia Newton-John Cancer Centre, Heidelberg, VIC, Australia.

Benjamin Harris (B)

Radiation Oncology Department, Olivia Newton-John Cancer Centre, Heidelberg, VIC, Australia.

Mark Tacey (M)

Office of Research, The Northern Hospital, Epping, VIC, Australia.
Melbourne School of Population and Global Health, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Carlton, VIC, Australia.

Drew Smith (D)

Radiation Oncology Department, Olivia Newton-John Cancer Centre, Heidelberg, VIC, Australia.

Nathan Lawrentschuk (N)

Austin Health, University of Melbourne, Melbourne, VIC, Australia.

Michal Elisabeth Schneider (ME)

Department of Medical Imaging and Radiation Sciences, Monash University, Melbourne, VIC, Australia.

Olivia Fraser (O)

Radiation Oncology Department, Olivia Newton-John Cancer Centre, Heidelberg, VIC, Australia.

Megan Hall (M)

Radiation Oncology Department, Olivia Newton-John Cancer Centre, Heidelberg, VIC, Australia.

Michael Chao (M)

Radiation Oncology Department, Olivia Newton-John Cancer Centre, Heidelberg, VIC, Australia.

Farshad Foroudi (F)

Radiation Oncology Department, Olivia Newton-John Cancer Centre, Heidelberg, VIC, Australia.

Trish Jenkins (T)

Radiation Oncology Department, Olivia Newton-John Cancer Centre, Heidelberg, VIC, Australia.

David Angus (D)

Radiation Oncology Department, Olivia Newton-John Cancer Centre, Heidelberg, VIC, Australia.

Morikatsu Wada (M)

Radiation Oncology Department, Olivia Newton-John Cancer Centre, Heidelberg, VIC, Australia.

Shomik Sengupta (S)

Austin Health, University of Melbourne, Melbourne, VIC, Australia.

Vincent Khoo (V)

Department of Clinical Oncology, Royal Marsden Hospital, London, United Kingdom.

Classifications MeSH